Squarepoint Ops LLC Buys 43,311 Shares of Tyra Biosciences, Inc. $TYRA

Squarepoint Ops LLC boosted its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 211.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,805 shares of the company’s stock after acquiring an additional 43,311 shares during the quarter. Squarepoint Ops LLC’s holdings in Tyra Biosciences were worth $2,038,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. California State Teachers Retirement System grew its holdings in shares of Tyra Biosciences by 55,815.5% in the 2nd quarter. California State Teachers Retirement System now owns 783,935 shares of the company’s stock worth $24,544,000 after purchasing an additional 782,533 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Tyra Biosciences during the 2nd quarter valued at about $334,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Tyra Biosciences by 125.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,688 shares of the company’s stock valued at $565,000 after buying an additional 9,856 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in Tyra Biosciences in the second quarter valued at about $237,000. Finally, Capstone Investment Advisors LLC bought a new stake in Tyra Biosciences during the second quarter worth about $321,000. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Stock Up 13.8%

Shares of NASDAQ:TYRA opened at $25.07 on Tuesday. Tyra Biosciences, Inc. has a 12 month low of $11.82 and a 12 month high of $40.65. The company’s 50-day moving average price is $28.27 and its two-hundred day moving average price is $31.77. The firm has a market cap of $1.50 billion, a P/E ratio of -10.45 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, equities analysts predict that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TYRA. Piper Sandler reaffirmed an “overweight” rating and set a $56.00 price objective on shares of Tyra Biosciences in a report on Tuesday, September 8th. Wolfe Research assumed coverage on Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. HC Wainwright decreased their price target on Tyra Biosciences from $45.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Finally, Wedbush reiterated an “outperform” rating and issued a $53.00 price objective on shares of Tyra Biosciences in a research report on Thursday, September 10th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tyra Biosciences has an average rating of “Moderate Buy” and an average target price of $47.88.

Tyra Biosciences Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.